To inquire about our available technologies, call our office (813) 745-6828
| Name & Description | Number |
|---|---|
| CLEC12A: Novel CLEC12A scFv Targeting CAR-T cells for Acute Myeloid Leukemia Immunotherapy | 21MB064 |
| CD40 Agonists for Improved ex vivo TIL Manufacturing | 21MA018N |
| T cells expressing anti-CD3 antibodies autoactivate and decrease expression of T cell receptors to treat GVHD, or make T cells suitable for off-the-shelf treatment of allogeneic subjects | 21MA013N |
| Human ITAM Mutated Variants For Better Intracellular Signaling Domains For Gamma-Delta CAR T-Cell Activation | 21MA008N |
| Cancer Vaccine Using Novel ESR1 Derived Peptides For Neoantigen Therapy | 20MB062N - VIDEO |
| Single-domain antibodies (nanobodies) targeting the notch ligand DLL4 to Disrupt the interaction of DLL4 and Notch1 for GVHD | 20MB053N |
| Bispecific Gamma Delta CAR-T Cells that Recognize CD33, CD123 and NKG2D Ligands for the Treatment of Acute Myeloid Leukemia | 20MB050N |
| Olfactory Receptor Targeting Chimeric Antigen Receptor Expressing T cell (CAR-T) for Solid Tumors | 20MA027 - VIDEO |
| CD33 CD123: Novel Bispecific CD33 CD123 scFv CAR-T Cells for Acute Myeloid Leukemia Immunotherapy | 20MA024 |
| HER-2: Combination Therapy of a HER2-DC1 Dendritic Cell Cancer Vaccine and a Probiotic | 20MA016N |
| TILs: 12 Chemokine Gene Expression Signature to Increase the Efficacy of Manufacturing Tumor Infiltrating Lymphocytes | 20MA013N |
| PERK, IRE1: Method of Enhancing Immunotherapy Using ER Stress Pathway Inhibitors | 20MA005 - VIDEO |
| PGC-1α: CAR-T Cells with Enhanced Metabolic Fitness due to Co-expression of Mutant PGC-1α | 19MB066 |
| N-Terminal Mutant PGC-1α Overexpression Enhances Metabolic Fitness Reducing CAR-T Exhaustion while Maintaining Proliferative Capacity | 19MB066T2 |
| Fucose Increases Tumor Cell HLA-DRB1 Expression Increasing CD4+ T-cell Activation with Synergistic Tumor Killing Activity with anti-PD1 Checkpoint Inhibitors | 19MB049N |
| Antibodies: Fully Human anti-BDNF Antibodies | 19MB048N |
| Antibodies: Fully Human anti-TSPAN7 Antibodies | 19MB047N |
| T-bet: T-bet Transcription Factor Armed CAR-T Cells Maintain Memory Phenotypes and Rescue CD4 Cells Leading to Increased Persistence | 19MA035N |
| EGFR, MUC1: Bispecific CAR-T Cell constructs (chimeric antigen receptors) that Recognize EGFR and MUC1 for the Treatment of Lung Cancer | 19MA033N |
| Bispecific T-Cell Engagers: B Cells Engineered to Express Bispecific T-Cell Engagers Result in Longer Half Lives | 19MA029N |
| NOTCH: Enhancing the Efficacy of Adoptive T-cell Immunotherapy Using Novel Notch Ligands | 19MA026N |
| aAPC: Artificial Antigen-Presenting Cells Expressing NKG2D Ligands for Producing anti-NKG2D CAR-T Cells | 19MA022N |
| NKG2D-Ligand: Enhancing Carcinoma Infiltration by NKG2D-Ligand Targeted CAR-T Cells by Co-Expression of the Chemokine Receptor CX3CR1 | 19MA015NT2 |
| GPC3: Enhancing Carcinoma Infiltration by Anti-GPC3 Targeted CAR-T Cells by Co-Expression of the Chemokine Receptor CX3CR1 | 19MA015N |
| B-RAF: Combination Therapy of TILs and BRAF Inhibitors to Treat BRAF Inhibitor-Resistant Metastatic Melanoma | 19MA007 |
| TILs: Enhancing the anti-tumor immunity of TILs by inhibiting Sirt2 | 18MB078 |
| 18MB072 Method of Using anti-CD277 Antibodies to Treat Cancer | 18MB072 |
| Antibodies: Fully Human anti-LAG3 Antibodies | 18MB062N |
| Antibodies: Fully Human anti-PD1 Antibodies | 18MB061 |
| Brain Mets: Lung Cancer Brain Metastases Targeting CAR-T Cell Constructs with Phage Display Derived Peptide Oligomers | 18MB059 |
| Glioma Stem Cell Targeting CAR-T Cell Constructs with Phage Display Derived Peptide Oligomers | 18MB054 |
| Suicide Switch: CAR-T cells can be Designed to Self-Destruct if Patient shows signs of Toxicity including graft-vs.-host-disease, cytokine release syndrome (CRS), and neurotoxicty | 18MB049N |
| TLR9 Ligand Trap: TLR9-IgG4 Fusion Protein to Neutralize Innate Immune Activation and Chronic Inflammation Contributing to MDS Pathogenesis | 18MB048N |
| Inflammasome: Method of Using Small-molecule Pyrin-domain Targeted NLRP3 Inflammasome Inhibitors to Neutralize Pyroptotic Cell Death Contributing to MDS Pathogenesis | 18MB044N |
| PSCA: Targeting Gamma Delta CAR-T Cells for the Treatment of Bone Metastatic Castrate-Resistant Prostate Cancer | 18MA037 - VIDEO |
| TILs: Method of Using a Demethylating Agent to Enhance STING Expression and TIL Anti-Tumor Activity in Melanoma | 18MA034N |
| TILs: TILs modified with CAR constructs result in CAR-TILs for Cancer Therapy | 18MA033 |
| NKG2D ligands: NKG2D Chimeric Antigen Receptor CAR-T Cells for Acute Myeloid Leukemia Immunotherapy | 18MA023 |
| aAPC: Artificial Antigen-Presenting Cells with Heparin-Binding Domain and Protein L for Producing CAR-T Cells | 18MA019N |
| TILs: The Use of Fucose to Increase TILs for the Immunotherapy of Melanoma | 17MB048 - VIDEO |
| CD99: Novel CD99 scFv Targeting CAR-T cells for Acute Myeloid Leukemia Immunotherapy | 17MB042 |
| CD99 CLEC12A: Novel Bispecific CD99 CLEC12A scFv CAR-T Cells for Acute Myeloid Leukemia Immunotherapy | 17MB042T2N |
| CLEC12A: Novel CLEC12A scFv Targeting CAR-T cells for Acute Myeloid Leukemia Immunotherapy | 17BM041 |
| Inflammasome: Stapled Peptides NLRP3 Inflammasome Inhibitors to Neutralize Pyroptotic Cell Death Contributing to MDS Pathogenesis | 17MB037 |
| CD123: CAR-T Cell Constructs that Recognize CD123 for the Treatment of Acute Myeloid Leukemia | 17MA031 |
| CD33, CD123: Bispecific CAR-T Cell Constructs that Recognize CD33 and CD123 for the Treatment of Acute Myeloid Leukemia | 17MA030T2 - VIDEO |
| CD33: CAR-T Cell Constructs that Recognize CD33 for the Treatment of Acute Myeloid Leukemia | 17MA030 |
| TILs: Simple and Rapid Method for Culture of TILs from Melanoma Tumor Fragments or Core Needle Biopsies of Solid Tumors | 17MA012 |
| CD3-CD28: Bispecific Antibody for the Generation of CAR-T cells for Cancer Immunotherapy | 17MA007 |
| IL-13Rα2: Targeting Chimeric Antigen Receptor Expressing T cell (CAR-T) for Melanoma Immunotherapy | 16MB069 |
| AaPC: Artificial Antigen-Presenting Cells for Expanding TILs and MILs in Cancer Immunotherapy | 16MB050 |
| aAPC: Artificial Antigen-Presenting Cells expressing CD3, CD28 and a Heparin-Binding Domain for Producing CAR-Ts | 16MB049 |
| TLS: Method of Using Chitosan Hydrogels with Chemokine-Releasing Microparticles or Stromal Cells to Bioengineer Tertiary Lymphoid Structures to Enhance the Immune System for Cancer Therapy | 16MA028N |
| TLR9: Targeting Chimeric Antigen Receptor-Expressing T cell (CAR-T) for MDS and AML Immunotherapy | 16MA025 |
| NLRP3 Inflammasome: Small Molecule Oral Signaling Inhibitor Icaritin Analog to Improve Hematopoiesis by Inhibiting NLRP3 Inflammasome Activation in MDS | 16MA007N |
| TIM3 Ligand Trap: TIM-3-IgG4 Fusion Protein for the Treatment of Anemia in Low- or Intermediate (Int)-risk MDS Patients | 16MA001 |
| Bromodomain: Ex vivo Activation and Expansion of Antigen Specific T cells in the Presence of a Bromodomain Inhibitor | 14MB100N |
| Cancer Vaccine: Full-Length Variant Survivin Vaccine Potentiates Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma | 14MB098 |
| HDAC6: Method of Using Histone Deacetylase 6 Inhibition for Enhancing T cell Function During Anti-Tumor Response and Tumor-Peptide Vaccination | 14MA037N |
| HDAC: Method of Using Histone Deacetylase as a Modulator of PDL1 Expression and Activity | 14MA027N |
| S100A9: CD33/IgG1 Chimera Antibody Trap to Neutralize S100A9 to Treat MDS | 13MB041 |
| Vaccine: Vaccines Using Synthetic Peptide-Poly IC Complexes that Elicit T-cell Responses Comparable to Live Vaccination | 11MA013 |
| Antibodies: Use of Antibodies to MARCO for Enhanced Dendritic Cell Vaccine Efficacy | 07MB004 |
